Treat to Target in Rheumatic Diseases: Rationale and Results - The Clinics: Internal Medicine 45-4 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 20, 2019--
The “Treat to Target in Rheumatic Diseases: Rationale and Results. The Clinics: Internal Medicine 45-4” book has been added to ResearchAndMarkets.com’s offering.
Guest edited by Dr. Daniel Aletaha, this issue of Rheumatic Disease Clinics will cover Treat to Target in Rheumatic Diseases with a focus on rationale and results. This issue is one of four selected each year by our series Consulting Editor, Dr. Michael Weisman. Articles explore diseases, including, but not limited to: History, Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthropathies, Systemic lupus erythematosus, PMR and GCA, Inflammatory Myopathies (PM/DM), Gout, and Subclinical Targets.
Daniel Aletaha is a consultant rheumatologist at the Medical University of Vienna and a renowned scientist in outcomes research, clinical trials, and translational research in rheumatoid arthritis and other inflammatory rheumatic diseases. He received academic degrees from the Medical University in Vienna, Duke University in North Carolina, and Danube University Krems. Daniel has spent more than two years at the National Institutes of Health in Bethesda, Maryland. Daniel Aletaha is a highly cited author of the field of rheumatology and author of more than 200 publications. He is also associate editor of Arthritis and Rheumatology and RMD Open, and editorial board member of a number of rheumatology specialty journals.
For more information about this book visit https://www.researchandmarkets.com/r/bvjz6t
View source version on businesswire.com:https://www.businesswire.com/news/home/20191220005166/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH OTHER HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 12/20/2019 05:22 AM/DISC: 12/20/2019 05:22 AM